Cancer Pain Epidemiology Summary

• Cancer pain remains a major unmet clinical need, affecting >70% of patients with advanced cancer, while improvements in cancer survival have increased the prevalence of persistent treatment- and disease-related pain.
• Increased survival with either life-prolonging or curative treatment results in increased numbers of patients experiencing persistent pain due to treatment, disease, or a combination of both. Approximately 5%–10% of cancer survivors have chronic severe pain that interferes significantly with functioning.
• Chemotherapy-induced peripheral neuropathy (CIPN) is a major complication that leads to cancer pain; there is a significant lack of treatment options for CIPN. Studies show that approximately two-thirds of the patients undergoing chemotherapeutic treatment for cancer suffer from CIPN

Cancer Pain Epidemiology Forecast in the 7MM

• 2025 Diagnosed Prevalent Cases of Cancer Pain: ~ USD XX million
• Cancer Pain Growth Rate (2026–2036): ~XX % CAGR

DelveInsight's "Cancer Pain Epidemiology Forecast – 2036" report delivers an in-depth understanding of the Cancer Pain, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Cancer Pain Understanding and Diagnostic Algorithm

Cancer Pain Overview

Cancer pain is a multifactorial and debilitating condition experienced by patients at various stages of malignancy, resulting from the tumor itself, cancer-related treatments, or a combination of both. It is defined by the International Association for the Study of Pain (IASP) as "an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage." Pain is among the most common and distressing symptoms in patients with cancer, with its prevalence increasing as the disease progresses, significantly impairing physical functioning, emotional well-being, and overall quality of life while also imposing a substantial burden on caregivers. The pathophysiology of cancer pain is heterogeneous and may involve nociceptive, neuropathic, inflammatory, or mixed mechanisms, making diagnosis and management particularly challenging.

Diagnosis

Diagnosis relies on a comprehensive clinical assessment that includes a detailed pain history, physical examination, evaluation of pain characteristics such as intensity, location, duration, and quality, and identification of the underlying etiology. Standardized assessment tools, including the Numeric Rating Scale (NRS), Visual Analog Scale (VAS), Verbal Rating Scale (VRS), and the Brief Pain Inventory (BPI), are routinely used to quantify pain severity and evaluate its impact on daily activities. Imaging modalities such as CT, MRI, PET, or bone scans, along with relevant laboratory investigations, may be employed to identify disease progression or treatment-related complications contributing to pain. Accurate and ongoing pain assessment is essential for developing individualized pain management strategies and optimizing clinical outcomes in patients with cancer.

Further details are provided in the report...

Cancer Pain Epidemiology

Key Findings from Cancer Pain Epidemiological Analysis and Forecast

• According to DelveInsight’s estimates the total number of incident cases of CIPN in the 7MM were ~1.6 million, in 2025.
• Cancer pain affects approximately 20–50% of patients with cancer, with the prevalence increasing to nearly 80% among those with advanced-stage disease, the majority of whom experience moderate-to-severe pain.
• In the United States, the direct tumor involvement accounted for 61.5% of cancer pain cases, followed by cancer treatment-related pain (32.0%) and pain unrelated to cancer or its treatment (6.5%), indicating that tumor progression remains the predominant cause of pain.
• In the United States, chemotherapy induced peripheral neuropathy accounted for nearly 85% of the cancer pain cases associated with cancer therapy, in 2023.
• Among severity-specific cases of cancer pain, severe cases accounted for 43.3%, followed by moderate cases (34.5%), and mild cases (22.2%), in the United States.

Scope of the Cancer Pain Report

• The report covers a segment of an executive summary, a descriptive overview of Cancer Pain, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Cancer Pain Epidemiology Report Insights

• Cancer Pain Patient Population Forecast

Cancer Pain Epidemiology Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• 11-year Forecast
• Patient Burden Trends (By Geography)

Explore DelveInsight's Cancer Pain Market Insights Report for comprehensive epidemiology, treatment trends, emerging therapies, competitive landscape, and market forecasts through 2036.

FAQs

• What are the disease risks, burdens, and unmet needs of cancer pain? What will be the growth opportunities across the 7MM concerning the patient population with cancer pain?
• What is the historical and forecasted cancer pain patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy Cancer Pain Epidemiology Report

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.